Dr. Mark D. Carlson, MD
Internal Medicine (Internal Medicine Physician)
- Medicare participating
At a glance
- Medical school
- Loma Linda University School of Medicine (1991)
- Years since graduation
- 35
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 46
Licensed in Texas since 2014, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1991Medical school: Loma Linda University School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
TX license Q2258 (first issued 2014; active) -
Geriatric Medicine (Family Medicine) Physician
TX license Q2258 (first issued 2014; active) -
Hematology & Oncology Physician
NE license 21230 · TX license Q2258 (first issued 2014; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Chi Health Bergan Mercy Omaha, NE
- The Nebraska Methodist Hospital Omaha, NE
Medical groups
- Be Well MD PLLC (4 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 46
- Services billed
- 14,307
- Patients’ average age
- 83
| Service | Times | Patients |
|---|---|---|
| Residence visit for established patient with low level of medical decision making, per day, if using time, at least 30 minutes | 119 | 32 |
| Residence visit for established patient with moderate level of medical decision making, per day, if using time, at least 40 minutes | 96 | 36 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 16 industry-funded studies in 2025, from 10 companies. The companies reported $2,078,450 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of Suzetrigine in Subjects With Painful Diabetic Peripheral Neuropathy
Vertex Pharmaceuticals Incorporated - A Phase 3, Open-label Study Evaluating the Long-term Safety and Effectiveness of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy
Vertex Pharmaceuticals Incorporated - A Study to Evaluate the Efficacy, Safety & Tolerability of Maridebart Cafraglutide in Adults With T2DM
Amgen Inc. - A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease
Eli Lilly and Company · Completed · NCT06538116 - A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With …
Janssen Research & Development, LLC - A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age
ModernaTX, Inc. · Terminated · NCT05085366 - A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19
ModernaTX, Inc. · Completed · NCT05815498 - A phase 3, 24-week, randomized, double-blind, placebo-controlled, para
GlaxoSmithKline, LLC. - A Phase 2, Randomized, Double-blind, Three-Arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of orally administered BMS-986368, a FAAH/MAGL Inhibitor, for the treatment of Agit…
Celgene Corporation - ITI-1284-101
Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.)
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.